

Curriculum Vitae

Prof. Dr. Bernhard Kutscher, Ph.D.



Personal Details

Private Address:	Stresemannstraße 9, 93477 Maintal, Germany, Tel. +49 6181 4 23 47-49, Mobil. +49 172 6 50 36 58 E-Mail. info@bk-hc-consulting.com
Date, Place of Birth:	23.09.1957, Frankfurt / Main
Marital Status:	married, 2 children
Nationality:	German
Languages:	German, English, French, Spanish

Education

- Chemistry study at the Johann-Wolfgang-Goethe-University, Frankfurt / Main, Germany.
- PhD. thesis on Peptide Synthesis and Medicinal Chemistry in 1984.

Summary

Accomplished business executive which has built, restructured and optimized divisions in Healthcare in order to drive value.

- As key executive contributed to the restructuring and subsequent divestiture of ASTA Medica Oncology by Degussa AG worth > \$ 700 million.
- As VP and GM R + D Europe managed complex role in combination with Oncology franchise.
- Leveraged Clinical Development and technical resources across various R + D sites in Germany, Belgium, France, Italy and Malta.
- Managed and executed headcount reductions and site closures with all necessary sensitivity to work council, unions and politicians.
- Liaison with politicians and affiliation with industry and biotech associations in order to create a fertile R + D environment.
- Via leadership teams, global projects and due diligence broad experience in Europe and US.

Entrepreneurial leader driving innovation and creation of product value in Pharma and Healthcare since 1984.

- Key contributor and inventor leading to various marketed products like Cetrorelix, Miltefosine, Azelastine, Retigabine and projects currently in clinical development like the anticancer products Indibulin and Perifosine.
- Successful product development focusing on new solutions, delivery systems and devices for patients with chronic diseases.
- Acknowledged international scientific leader with strong record of innovation exemplified by scientific publications, presentations and IP.
- Provided strategic vision and leadership to realign product portfolios; managed product in- and out-licensing, established project and alliance management.
- Established through Innovation Council new R + D productivity metrics and Corporate Technology Award.

Strong inspirational team leader, who has recruited, retained and motivated employees and worked with cross-functional teams to execute R + D, corporate and business development plans in alignment with commercial strategies

- As Managing Director Baxter Oncology with formal responsibility for 450 + employees in Halle and Bielefeld / Germany.
- Managed company operations at multiple sites and forged cooperation and integration across.
- Very effective in creating an atmosphere of innovation, trust and creativity while at the same time implementing operational improvements and excellence.
- As VP R + D Europe managed annual budgets > € 50 million, doubled headcount between 2004 – 2010 and hence designed, constructed and moved into new state-of-the-art R + D center in Belgium for 480 + Baxter employees.

Professional Experience

November 2001 – September 2012 Baxter International, Chicago, USA

\$ 14 billion global diversified Healthcare company that develops, manufactures and markets products with medical devices, pharmaceuticals and biotechnology that advance patient care worldwide.

December 2003 – September 2012

Vice President Baxter R + D Europe, Belgium

Led a fully integrated R + D centre as General Manager with a budget > \$ 60 million and a total of 250 + employees. Broad scope of responsibilities including pilot plant, QA, IT and EHS. Reporting to CSO Baxter International, Member of Baxter's Global Senior Management Team and Innovation Council. 15 management direct reports (including one VP).

- Reinvigorated Baxter R + D Europe applying core competencies on new product development as well as technical support for the global franchises.
- Successfully launched various innovative Drug, Container and Medical Device products.
- Focused development on Ready-to-use formulations, Homecare and Compounding services.
- Negotiated and received from Belgian Government subsidies for innovative R + D in the range of > \$ 3 million / year.
- Introduced new processes as well as productivity metrics for R + D and technology alliances with milestone achievement > 90 %.
- Recruited international talent, doubled headcount and integrated teams from various R + D sites like Malta, Italy and France.
- Designed and organized move into new, ISO 13485 certified R + D center for 480 + employees.
- Constructed largest stability chambers in European Healthcare Industry.

April 2003 – January 2012

Managing Director Baxter Oncology GmbH

Responsibility for API and Fill +Finish Oncology Manufacturing Plants in Halle and Bielefeld / Germany with 450 + employees.

- Established Custom Manufacturing (CM) and Project Management for third party services. Achieved growth of Oncology franchise in both captive use and CM.
- Restructured Oncology R+D and closed Frankfurt site with all necessary sensitivity to work council, unions and politicians.

April 2003 – April 2009

Managing Director Baxter Deutschland Holding

Supervision of all Baxter Germany legal entities with 1500+ employees and total sales > \$ 450 million.

- Increased value by restructuring operations and site consolidation.
- Developed the entire business by sales into second largest country operation worldwide.
- Implemented new communication tools across new structure.

November 2001 – August 2011

Vice President R + D Baxter Oncology

150 employees at peak with a \$ 50 million R + D budget and global responsibility including Drug Safety / Pharmacovigilance and Regulatory Affairs. Reporting to Divisional President in the Chicago and Frankfurt headquarters.

- Designed, implemented and established portfolio management and aligned goals with franchise.
- Created Alliance and cooperated with various universities and biotech companies.
- Successfully led business development initiatives with in- and out-licensing deals.
- Established international Scientific Advisory Board to consult on five global clinical research projects in Phase I – III.

June 1984 – October 2001

Degussa AG / ASTA Medica AG, Frankfurt / Dresden Germany

DM 14 billion multinational specialty chemicals leader with ASTA Medica as pharmaceutical branch. ASTA Medica has a strong legacy as pioneer in the field of cytotoxic agents for cancer treatment.

September 2000 – October 2001

Vice President R+D ASTA Medica Oncology

200 employees with global responsibility for R + D incl. Patent Department and Quality Assurance. Reporting to CEO ASTA Medica.

- Achieved in-licensing of exciting Phase III from US biotech company.
- Established project management with tools to manage and optimize a balanced portfolio of 20+ preclinical, clinical and LCM projects.
- Increased portfolio and company value with international registrations.
- Presented the company as one of the senior executives to seven potential international buyers.
- Concluded divestiture with acquisition of ASTA Medica Oncology by Baxter International for > \$ 700 million.

March 1999 – June 2000

Corporate Development Degussa-Hüls

Incremental role at headquarter reporting to Head of Corporate Development Degussa-Hüls and CEO ASTA Medica.

- Responsible for strategic management "Pharmaceuticals Business".
- Introduced key performance metrics and optimized portfolio of ASTA Medica.
- Played key role in carve-out and divestiture process as interface to shareholder Degussa-Hüls, the financial advisor Morgan Stanley and potential investors.

October 1995 – August 2000

Head of Chemical Research / Medicinal Chemistry ASTA Medica Group

200 employees in R + D centers Frankfurt and Dresden with global responsibility for Chemistry from "grammes" to "tonnes". Reporting to Global Head R + D.

- Integrated R + D of Arzneimittelwerk Dresden after acquisition.
- Successfully developed and launched Cetrorelix in cooperation with Nobel Prize laureate Prof. Andrew Schally / Tulane University, New Orleans.
- Steering committee member of SUGEN and Schering AG research cooperation.
- Responsibility for spin-off / IPO of the biotech subsidiary Europeptides / Paris.

October 1987 – September 1995

Head of Medicinal Chemistry ASTA Medica AG

Employees in Frankfurt and Bielefeld reporting to Head of R + D.

- Established Drug Discovery with target oriented HTS and combinatorial chemistry.
- Invented the innovative antiepileptic Retigabine and oral anticancer Perifosine.
- Cooperated with NIH and NCI in clinical drug development of antiepileptic and anticancer drugs. Registration and launch of Miltefosine as new anticancer drug.
- Steering committee member of a consortial collaboration on protein design.

June 1984 – September 1987

Laboratory Manager Pharmaceutical Chemistry Degussa AG

3 technicians and engineers in Frankfurt and Hanau; reporting to Head of Pharmaceutical Chemistry.

- Heterocyclic organic chemistry and natural product synthesis.
- Pilot plant activity with extraction in ton scale.

Experience and Affiliations

- Lecturer at the Technical University Munich in “Industrial Drug Research and Development” since 1992.
- Honorary professorship at TU Munich since 1996.
- Consultant for Biotech Companies.
- Chairman of VCI / DIB’s working group “Biotechnologie/Gentechnik”.
- Vice-Chairman of DECHEMA’s “Fachausschuss Biotechnologie”.
- Member of a Biotech-Delegation of the Hessian Minister of Economics visiting USA.
- Member of a Delegation of the Federal Minister of Research and Technology visiting China.
- Board member of the “Medicinal Chemistry Section” of the German Chemical Society.
- German Chemical Society (GDCh)
- German Biological Chemistry Society (GBCh)
- DECHEMA
- European Peptide Society (EPS)
- American Chemical Society (ACS)
- More than 100 publications and presentations, approx. 50 patents and applications.
- Attendance and presentation in annual meetings like ASCO, ESMO as well as further R + D conferences.
- Co-author of the book “Pharmaceutical Substances”, Publ. Thieme Verlag, 1999, 2001 and 2009.